Kexing Pharmaceutical

Kexing Pharmaceutical (stock code: 688136) is an innovative international biopharmaceutical enterprise integrating research, development, production, and sales of recombinant proteins, multifunctional antibodies, targeted delivery therapies, and more. It focuses on therapeutic areas such as anti-tumor, autoimmunity, and antiviral treatments, and addresses unmet clinical needs by building cutting-edge biotechnology platforms for novel proteins, novel antibodies, and nucleic acid drugs, developing precision therapies and novel targeted delivery drugs. Adhering to the dual-driven development model of "innovation + internationalization," it is committed to becoming a high-quality biopharmaceutical provider serving global patients.

Kexing Pharmaceutical has established multiple R&D centers globally, including Shenzhen Pharmaceutical Research Institute, Shandong Technology Center, Guangzhou Carrier Vaccine R&D Center, and US R&D Center. The company has built three major biotechnological systems: prokaryotic cells, eukaryotic cells, nucleic acid and viruses, and successfully established several domestically and internationally leading technology platforms such as KX-FUSION protein technology platform, KX-BODY antibody technology platform, KExosome delivery technology platform, microecological preparation R&D and industrialization technology platform, and carrier vaccine technology platform. Focusing on biopharmaceuticals and following R&D strategic planning, the company achieves a echelon, serialized, and progressive product layout. Combining "independent R&D + cooperative development" models, it enriches the R&D pipeline and accelerates the industrialization of cutting-edge technologies. Currently, there are more than ten innovative projects in R&D, with multiple pipelines adopting a dual-filing strategy in China and the US, including GB05 human interferon α1b inhalation solution (already in Phase III clinical trials in China), and GB18 cancer cachexia drug (target: GDF-15).

The company has an R&D team of nearly 200 people, with over 60% holding master's degrees or above. It owns 65 patents. Its R&D innovation and technical capabilities have been widely recognized: in 2017, it was designated as "Shandong Provincial Enterprise Technology Center"; in 2018, as "Jinan Protein Drug Engineering Laboratory"; in 2020, as "Guangdong Provincial Genetic Engineering Recombinant Protein Drug Engineering Technology Center", "Shandong Provincial Protein Drug Engineering Laboratory", and "Shenzhen Postdoctoral Innovation Practice Base"; in 2023, it was recognized as an "Innovative SME", "Specialized, Refined, Distinctive, and Innovative SME", and "Shandong Provincial Engineering Research Center for Protein Drugs". Additionally, the company's brand has been ranked among the TOP20 Chinese biopharmaceutical enterprises (including blood products, vaccines, insulin, etc.) in the China Pharmaceutical Industry Top 100 list for three consecutive years.

The company has 31 core products, including recombinant protein drugs "Human Erythropoietin (Epiao?) ", "Human Interferon α1b (Sai Ruo Jin)", "Human Granulocyte Colony-Stimulating Factor (Bai Te Xi)", microecological preparation "Clostridium Butyricum and Bifidobacterium (Chang Le Kang)", proprietary Chinese medicine "Ke Huang Capsule", chemical drug "Entecavir (Sai Gan Su)", as well as imported products "Albumin-bound Paclitaxel (Apexelsin)", "Infliximab (Lei Ting)", "Bevacizumab (Arketin)", "Adalimumab (Ahrasin)", "Liraglutide (Exinkira)", "Semaglutide", "Denosumab", "Aflibercept", etc.

In recent years, Kexing Pharmaceutical's business has continued to grow rapidly, with core products firmly ranking among the top in domestic counterparts, covering approximately 20,000 terminals across provinces and cities nationwide, including about 8,000 hospitals, 7,700 third-party terminals, and over 3,000 pharmacies. According to data from Beijing Guoyao Chengxin, in 2024, the market share of the company's "Sai Ruo Jin®" among domestic short-acting injectable human interferons ranked first; "Epiao?®" ranked second in the domestic human erythropoietin market; "Lei Ting®" ranked second in the domestic infliximab market. Since 2023, the company has actively expanded its e-commerce business, with "Chang Le Kang®" probiotics consistently ranking in the top three on JD.com's diarrhea medication list for a long time.

Kexing Pharmaceutical has over 20 years of experience in biopharmaceutical going global, having achieved market access and sales in more than 70 countries and regions worldwide, including the EU, Brazil, Egypt, and the Philippines. Among them, EPO products have become leading erythropoietin brands in countries such as Brazil and the Philippines. The overseas team construction has achieved a "localized" talent structure upgrade, driving incremental development in overseas markets. The company has established and operates multiple overseas subsidiaries in Germany, Brazil, Singapore, etc. Since its listing on the Science and Technology Innovation Board, the company has seized new opportunities in the rapid development of biotechnology, building a high-quality medicine going global platform of "global selection + global coverage". Focusing on anti-tumor, autoimmune, and metabolic disease areas, it actively introduces biosimilars and high-end complex preparations, has reached overseas commercialization cooperation with many well-known domestic pharmaceutical companies, and through its global marketing network layout and deep cultivation of key overseas markets, with high-standard products and services, it has established stable global cooperative relations, gradually developing into a value platform for Chinese high-quality medicines going global. In May 2025, under the guidance of the Shenzhen Medical and Medical Device Industry Office, Kexing Pharmaceutical's wholly-owned subsidiary - Shenzhen Kexing Pharmaceutical Co., Ltd. served as the initiating unit of the Shenzhen Medical Device Industry Going Global Alliance, providing one-stop going global services for medical device enterprises.

Adhering to the mission of "Precise Pharmaceutical Manufacturing, Precise Medication, Safeguarding Health", Kexing Pharmaceutical contributes to global health and benefits more doctors and patients.